 Zymeworks NYSE: ZYME stock is climbing higher on Wednesday after the company signed a licensing agreement with Jazz Pharmaceuticals NASDAQ: JAZZ . This agreement has Jazz Pharmaceuticals acquiring development and commercialization rights to zanidatamab. 